Natco Pharma's API facility near Hyderabad gets 6 USFDA observations
The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust
The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust https://ift.tt/2MVdxJp August 11, 2019 at 08:24PM
The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust https://ift.tt/2MVdxJp August 11, 2019 at 08:24PM
Comments
Post a Comment